ClinicalTrials.gg
CompletedNCT01368523Updated Nov 16, 2016

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

A Phase 4 interventional study of nilotinib in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-16.

Primary conditionBlast CrisisRegistry: Leukemia, Myelogenous, Chronic, BCR-ABL PositiveReclassifiedWhy we changed it
Registry
Leukemia, Myelogenous, Chronic, BCR-ABL Positive — the first condition term the registry derived for this study.
ClinicalTrials.gg
Blast Crisis
Why
  1. The study's title name Blast Crisis, a narrower term within Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to provide patients with imatinib resistant/intolerant chronic myeloid leukemia - in blast crisis, accelerated phase and chronic phase, who have been previously enrolled to CAMN107A2109 and benefit from the treatment, with access to nilotinib (AMN107) in Poland until such time as the treatment with this drug is financed by the National Health Found in Poland (via 'therapeutic program') or for a period of 18 months, whichever comes first.

02

Conditions studied

  • Chronic Myelogenous Leukemia

Browse trials for

Keywords

  • Chronic Myelogenous Leukemia
  • chronic phase
  • accelerated phase
  • blastic phase
  • nilotinib
03

In context

Blast Crisis Reclassified

361 studies on the registry are indexed under Blast Crisis; 16 are open to participants now.

This study's enrollment of 19 is below the median of 36 across 264 interventional studies indexed under Blast Crisis.

Browse Blast Crisis studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Blast Crisis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Imatinib - resistant or - intolerant Philadelphia chromosome-positive CML in chronic phase, accelerated phase or in blast crisis patients previously enrolled to CAMN107A2109 trial in Poland and continuing the treatment with nilotinib at the time of enrollment for this trial.
  2. In the opinion of the investigators would benefit from the further treatment with nilotinib
  3. No evidence of extramedullary leukaemic involvement, with the exception of liver and spleen
  4. Males or females ≥18 years of age
  5. of ≤ 2
  6. ≤ 450 msec on the average of three serial baseline (using the QTcF formula).
  7. Patients must have the following laboratory values:

    • Potassium within normal limits or corrected to within normal limits with supplements prior to the first dose of study medication
    • Total calcium (corrected for serum albumin) within normal limits or correctable with supplements
    • Magnesium within normal limits or corrected to within normal limits with supplements prior to the first dose of study medication
    • Phosphorus ≥ LLN or correctable with supplements
    • and AST ≤ 2.5 x or ≤ 5.0 x ULN if considered due to tumour
    • Alkaline phosphatase ≤ 2.5 x ULN unless considered due to tumour
    • Serum ≤ 1.5 x ULN
    • Serum creatinine ≤ 1.5 x ULN or 24-hour ≥ 50 ml/min
    • Serum amylase ≤ 1.5 x ULN and serum lipase ≤ 1.5 x ULN
  8. Written signed and dated prior to any study procedures being performed.

Exclusion criteria

Exclusion Criteria:

  1. Known T315I mutations
  2. Impaired cardiac function including any one of the following:

    • \< 45% or below the institutional lower limit of the normal range (whichever is higher) as determined by echocardiogram
    • Inability to determine the on
    • Complete left bundle branch block
    • Use of a ventricular-paced pacemaker
    • Congenital long QT syndrome or a known family history of long QT syndrome
    • History of or presence of ventricular or atrial tachyarrhythmias
    • Clinically significant resting brachycardia (\< 50 beats per minute)
    • QTc > 450 msec on the average of three serial baseline ECG (using the QTcF formula). If QTcF > 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc.
    • History of clinically documented myocardial infarction
    • History of unstable angina (during the last 12 months)
    • Other clinically significant heart disease (e.g. congestive heart failure or uncontrolled hypertension).
  3. Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required)
  4. Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection)
  5. History of significant congenital or acquired bleeding disorder unrelated to cancer
  6. Previous radiotherapy to ≥ 25% of the bone marrow
  7. Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from prior surgery
  8. History of non-compliance to medical regimens or inability to grant consent
  9. Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)
  10. Patients actively receiving therapy with strong inhibitors (e.g, erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug or who are within 5 half-lives of the last dose of this medication prior to starting study drug.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    nilotinib

    Drug: nilotinib

Interventions

06

What researchers measure

Primary outcomes

  1. hematologic response

    Time frame: 18 months

Secondary outcomes

  1. cytogenetic response

    Time frame: 18 months

07

Study locations

3 sites
  • Novartis Investigative Site
    Gdansk, Poland
  • Novartis Investigative Site
    Poznan, Poland
  • Novartis Investigative Site
    Warsaw, Poland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008 and a primary completion of Jan 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2011
First posted
Jun 8, 2011
Start
Dec 2008
Primary completionActual
Jan 2010
Last update
Nov 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01368523
Responsible party
Sponsor
First posted
Jun 8, 2011
Start date
Dec 2008
Primary completion
Jan 2010
Last update
Nov 16, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion